van Rhee, F., Casper, C., Voorhees, P. M., Fayad, L. E., van de Velde, H., Vermeulen, J., . . . Kurzrock, R. (2015). A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget.
Citação norma Chicagovan Rhee, Frits, et al. "A Phase 2, Open-label, Multicenter Study of the Long-term Safety of Siltuximab (an Anti-interleukin-6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease." Oncotarget 2015.
Citação norma MLAvan Rhee, Frits, et al. "A Phase 2, Open-label, Multicenter Study of the Long-term Safety of Siltuximab (an Anti-interleukin-6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease." Oncotarget 2015.